Anavex Life Sciences Corp (AVXL)

[RedShoulder]

Right, just finished listening.

Great questions and confident objective positive answers from Missling.

Given the highly positive PDD data there is no longer a need for the Parkinson’s imaging study. Now just going for two pivotal studies one in PD and the other PDD.

Possibly apply for approval already based on the PDD P2 better than expected biomarker supported results.

Investor, many thanks for the read.

I had hoped based on the very positive Ph-2 results for PDD and Secondary end points for PD also positive, that Missling would opt for two separate Ph-3 pivotal trials.

That sounds like very good news to me, a PDD Ph-3 and a PD Ph-3. And to go along a Alzheimers Ph-2b/3; all potentially pivotal.

Three of the biggest revenue markets in the entire CNS space in potentially pivotal Ph-3 trials soon. The impact of that fact cannot be overstated.